Clinical trials: Duodenal Diseases
Gastric or Duodenal Ulcers
Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs
The purpose of this study is to investigate the safety and efficacy of long-term administration of lansoprazole (Takepron) therapy for up to 12 months in the routine clinical setting in patients receiving oral non-steroidal…
- Trial name
- NCT02099708
- Testing
- Lansoprazole
- Volunteers
- 3,502 people
- Sponsor
- Takeda
Peptic Ulcer
Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers
The sutdy aims to to demonstrate the non-inferiority of JP-1366 10 mg compared to Lanston Capsule 15 mg in preventing NSAIDs-induced peptic ulcers and to compare/evaluate the efficacy and safety of JP-1366 10 mg.
- Trial name
- NCT06439563
- Testing
- JP-1366 10 mg, Lanston Capsule 15 mg
- Where
- South Korea
- Volunteers
- 364 people
- Sponsor
- Onconic Therapeutics Inc.
Prevention
Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin
To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from…
- Trial name
- NCT01069939
- Testing
- Esomeprazole
- Where
- 46 sites in Japan, South Korea and 1 more
- Volunteers
- 427 people
- Sponsor
- AstraZeneca
Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract
Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers
Comparative study of the pharmacodynamic parameters and pharmacodynamic equivalence (bioequivalence) of drug Antareit 800 mg/10 ml oral suspension and drug Riopan 800 mg chewable tablets in healthy volunteers.
- Conditions
- Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract, Symptomatic Treatment of Gastric and Duodenal Ulcers
- Trial name
- NCT06098742
- Testing
- Antareit
- Where
- 2 sites in Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Esophagitis, Reflux, Esophagitis, Peptic
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
- Trial name
- NCT00255151
- Testing
- Dexlansoprazole MR
- Where
- 100 sites in United States
- Volunteers
- 451 people
- Sponsor
- Takeda
Obesity, Morbid
Procedure for Duodenal-Ileal Diversion for Patients With Weight Regain Following Sleeve Gastrectomy
Study will monitor weight loss and metabolic indicators for subjects in single-center, single arm trial.
- Trial name
- SNAP-PS (NCT05049824)
- Testing
- Self Forming Magnetic (SFM) Anastomosis System
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- GI Windows, Inc.
Iron Deficiency Anemia
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects
To evaluate the efficacy and safety of 12 weeks treatment with Ferrous (II) Glycine Sulphate Complex in comparison to Polyferose capsules in Chinese subjects with manifest Iron Deficiency Anemia.
- Trial name
- NCT01425463
- Testing
- Ferrous (II) Glycine Sulphate Complex, Polyferose
- Where
- 15 sites in China
- Volunteers
- 256 people
- Sponsor
- Sanol GmbH
Gastric Ulcers, Duodenal Ulcers
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)
The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD), compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of non-steroidal…
- Trial name
- NCT01452750
- Testing
- TAK-438, Lansoprazole
- Where
- 102 sites in Japan
- Volunteers
- 642 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus, Type2diabetes
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
- Conditions
- Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes
- Trial name
- NCT06267391
- Testing
- Endogenex Treatment
- Where
- 44 sites in United States, Australia
- Volunteers
- 350 people
- Sponsor
- Endogenex, Inc.
Gastric Ulcer, Duodenal Ulcer
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy
The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term NSAID therapy will be investigated.
- Trial name
- NCT01568385
- Testing
- TAK-438
- Where
- 18 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Takeda
Gastric Ulcer
Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer
The purpose of this study is to assess the efficacy of esomeprazole 20 mg dosed once daily and ranitidine 150 mg dosed twice daily through 4 weeks of treatment for the healing of gastric ulcers in patients receiving daily…
- Trial name
- NCT00401752
- Testing
- Esomeprazole, Ranitidine
- Where
- 9 sites in China, Hong Kong
- Volunteers
- 397 people
- Sponsor
- AstraZeneca
Gastric Ulcer, Duodenal Ulcer
A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy
The purpose of this study is to study the safety and efficacy of TAK-438, once daily (QD), in participants with a history of gastric or duodenal ulcer requiring long-term low-dose aspirin therapy will be investigated.
- Trial name
- NCT01568398
- Testing
- TAK-438
- Where
- 19 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Takeda
Gastric Ulcers, Duodenal Ulcers
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD) compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.
- Trial name
- NCT01452763
- Testing
- TAK-438, Lansoprazole
- Where
- 76 sites in Japan
- Volunteers
- 621 people
- Sponsor
- Takeda
Gastric Ulcer
A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet
An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual Tablets in Healthy Adult Volunteers
- Trial name
- NCT02759224
- Testing
- BRI-1501, Lafutidine, Irsogladine maleate
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Type 2, Noninsulin-Dependent Diabetes Mellitus
Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)
The purpose of this study is to demonstrate the efficacy and safety of the Fractyl duodenal mucosal resurfacing (DMR) Procedure using the Revita System compared to a sham procedure for the treatment of uncontrolled type 2…
- Trial name
- NCT02879383
- Testing
- DMR Procedure
- Where
- 11 sites in Belgium, Brazil and 3 more
- Volunteers
- 109 people
- Sponsor
- Fractyl Health Inc.
Reflux Esophagitis
The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis
To evaluate the efficacy, safety, and cost-effectiveness of DWP14012 40 mg compared to esomeprazole magnesium enteric-coated tablets for the treatment of reflux esophagitis.
- Trial name
- NCT05813561
- Testing
- DWP14012
- Where
- China
- Volunteers
- 332 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca
Gastric Ulcer
Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.
This clinical trial is an open-label, randomized, fasting, single-dose, two-sequence, two-period, crossover study in healthy subjects to evaluate the bioequivalence of "Vonopzan Tablets 20 mg(Vonoprazan Fumarate)" of Hanlim…
- Trial name
- NCT06642987
- Testing
- Vonoprazan Test 20mg, Vonoprazan Reference 20mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Helicobacter Pylori
Feasibility Study of Phototherapy System to Treat H Pylori
This purpose of this study is to determine whether phototherapy can be used to safely and effectively treat H pylori.
- Trial name
- NCT00306280
- Testing
- Phototherapy
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LumeRx
Gastric Ulcer
Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'
The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.
- Trial name
- NCT07385235
- Testing
- AD-115A, AD-1151
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Addpharma Inc.